Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus
Sponsor: Response Pharmaceuticals
A PHASE2 clinical study on Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by Response Pharmaceuticals and has accumulated 9 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Dec 2023 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Response Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .